Company intelligence / Profile preview
Replimune Group, Inc.
Woburn, Massachusetts, United Statesreplimune.com ↗
- Ownership
- Public · REPL
- Employees
- ~331
- Development stage
- Other
01
Overview
Replimune has a Biologics License Application under priority review for RP1 for the treatment of advanced melanoma. The company has multiple ongoing clinical programs evaluating their therapies in various solid tumor cancers, both as single agents and in combination with other immunotherapies.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic immunotherapiesOncolytic viruses
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Financials
- Market cap
- $1.9B
- Total revenue
- $0
- Enterprise value
- $1.7B
Beyond the preview
Go deeper on Replimune Group, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Replimune Group, Inc..